Balaxi Pharmaceuticals Ltd, with a market cap of over ₹200 crore and PE of 12x, reported FY25 net sales of ₹293 crore, up 22%, and net profit of ₹25 crore, up 1,350%. Q2FY26 sales stood at ₹56.18 crore. The company approved a $4 million infusion in Balaxi Global FZCO and completed its Jadcherla plant setup.